Novel protein toxin-based strategy for development of cytotoxic T lymphocyte vaccines

Archivum Immunologiae et Therapiae Experimentalis

Volumn 46, Issue 6, 1998, Pages 341-346

  Wiȩdłocha, Antoni ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antigen; CD8+ T cells; MHC class I; Protein toxins; Vaccine

Indexed keywords

BACTERIAL TOXIN; BACTERIAL VACCINE; HLA ANTIGEN CLASS 1;

ANIMAL; CD8+ T LYMPHOCYTE; CYTOTOXICITY; HUMAN; IMMUNOLOGY; REVIEW;

ANIMALS; BACTERIAL TOXINS; BACTERIAL VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS;

EID: 0032238115     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. ARORA N., KUMPEL K. R., SINGH Y. and LEPPLA S. H. (1992): Fusion of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J. Biol. Chem., 267, 15542-15548.
2. ARORA N. and LEPPLA S. H. (1993): Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J. Biol. Chem., 268, 3334-3341.
3. ARORA N., WILLIAMSON L. C., LEPPLA S. H. and HALPERN J. L. (1994): Cytotoxic effect of a chimeric protein consisting of tetanus toxin light chain and anthrax toxin lethal factor in nonneuronal cells. J. Biol. Chem., 269, 26165-26171.
4. BABA T. W., TRICHEL A. M., AN L., LISKA V., MARTIN L. N., MURPHEY-CORB M. and RUPRECHT R. M. (1996): Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science, 272, 1486-1489.
5. BALLARD J. D., COLLIER J. R. and STARNBACH M. N. (1996): Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo. Proc. Natl. Acad. Sci. USA, 93, 12531-12534.
6. BLANKE S. R., MILNE J. C., BENSON E. L. and COLLIER J. R. (1996): Fused polycationic peptide mediates delivery of diphtheria toxin A chain to the cytosol in the presence of anthrax protective antigen. Proc. Natl. Acad. Sci. USA, 93, 8437-8442.
7. CEASE K. B. and BERZOFSKY J. A. (1994): Toward a vaccine for AIDS: the emergence immunobiology-based vaccine development. Annu. Rev. Immunol., 12, 923-989.
8. CHEEVER M. A., DISIS M. L., BERNHARD H., GRALOW J. R., HAND S. L., HUSEBY E. S., QIN H. L., TAKAHASHI M. and CHIEN W. (1995): Immunity to oncogenic proteins. Immunol. Rev., 145, 33-59.
9. DANIEL M. D., KIRCHHOFF F., CZAJAK S. C., SEGHAL P. K. and DESROSIERS R. C. (1992): Protective effects of a live attenuated siv vaccine with a delection in the nef gene. Science, 258, 1938-1941.
10. DARJI A., GUZMAN C. A., GERSTEL B., WACHHOLZ P., TIMMIS K. N., WEHLAND J., CHAKRABORTY T. and WEISS S. (1997): Oral somatic transgene vaccination using attenuated S. typhimurium. Cell, 91, 765-775.
11. DONNELLY J. J., ULMER J. B., HAWE L. A., FRIEDMAN A., SHI X. P., LEANDER K. R., SHIVER J. W., OLIFF A. I., MARTINEZ D., MONTGOMERY D. and LIU M. A. (1993): Targeted delivery of peptide epitopes to class I major histocompatibility molecules by a modified Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 90, 3530-3534.
12. DONNELLY J. J., ULMER J. B., SHIVER J. W. and LIU M. A. (1997): DNA vaccines. Annu. Rev. Immunol., 15, 617-648.
13. GOLETZ T. J., KLIMPEL K. R., ARORA N., LEPPLA S. H. and KEITH J. M. (1997): Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Proc. Natl. Acad. Sci. USA, 94, 12059-12064.
14. HAZES B. and READ R. J. (1997): Accumulating evidence suggests that several AB-toxins subvert the endoplasmatic reticulum-associated protein degradation pathway to enter target cells. Biochemistry, 36, 11051-11054.
15. HEWLETT E. L. and MALONEY N. J. (1995): Adenylyl cyclase toxin from Bordetella pertusis. In MOSS J., VAUGHAN M., IGLEWSKI B. and TU A. T. (eds.): Bacterial toxins and virulence factors in disease. Dekker, New York, 425-439.
16. KAGI D., LEDERMAN B., BURKI K., ZINKERNAGEL R. M. and HENGARTNER H. (1995): Lymphocyte-mediated cytotoxicity in vitro and in vivo mechanism and significance. Immunol. Rev., 146, 95-115.
17. KLINGENBERG O. and OLSNES S. (1996): Ability of methotrexate to inhibit translocation to the cytosol of dihydrofolate reductase fused to diphtheria toxin. Biochem J., 313, 647-653.
18. LEHNER P. J. and CRESSWELL P. (1996): Processing and delivery of peptides presented by MHC class I molecules. Curr. Opin. Immunol., 8, 59-67.
19. LEPPLA S. H. (1995): Antrax toxin. In MOSS J., IGLEWSKI B., VAUGHAN M. and TU A. T. (eds.) Bacterial toxins and virulena factors in disease. Dekker, New York, 543-572.
20. MELIAN A., BECKMAN E. M., PORCELLI S. A. and BRENNER M. B. (1996): Antigen presentation by CD1 and MHC-encoded class I-like molecules. Curr. Opin. Immunol., 8, 82-88.
21. MESCHER M. F. (1995): Molecular interaction in the activation of effector and precursor cytotoxic T lymphocytes. Immunol. Rev., 146, 177-210.
22. MOORE M. W., CARBONE F. R. and BEVAN M. J. (1988): Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell, 54, 777-785.
23. OLSNES S., KLINGENBERG O., MUNOZ R., FALNES P. Ø. and WIȨDŁOCHA A. (1997): Toxins as transporting tools. In AKTORIES K.: Bacterial toxins. Chapman and Hall, Weinheim, 273-294.
24. OLSNES S., VAN DEURS B. and SANDVIG K. (1993): Protein toxins acting on intracellular targets: cellular uptake and translocation to the cytosol. Med. Microbiol. Immunol., 182, 65-81.
25. OLSNES S., STENMARK H., MOSKAUG J. Ø., MCGILL S., MADSHUS I. H. and SANDVIG K. (1990): Protein toxins with intracellular targets. Microb. Pathog., 8, 163-168.
26. PASTAN I., CHAUDHARY V. and FITZGERALD D. J. (1992): Recombinant toxins as novel therapeutic agents. Annu. Rev. Biochem., 61, 331-354.
27. PETOSA C., COLLIER J. R., KLIMPEL K. R., LEPPLA S. H. and LIDDINGTON R. C. (1997): Crystal structure of the anthrax toxin protective antigen. Nature, 385, 833-838.
28. RAPAK A., FALNES P. Ø. and OLSNES S. (1997): Retrograde transport of mutant ricin to the endoplasmic reticulum with subsequent traslocation to cytosol. Proc. Natl. Acad. Sci. USA, 94, 3783-3788.
29. SANDVIG K., GARRED Ø., PRYDZ K., KOZLOW J. V., HANSEN S. H. and VAN DEURS B. (1992): Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature, 358, 510-511.
30. + T cell epitope from lymphocytic choriomeningitis virus. Proc. Natl. Acad. Sci. USA, 94, 3314-3319.
31. STENMARK H., MOSKAUGH J. Ø., MADSHUS I. H., SANDVIG K. and OLSNES S. (1991): Peptides fused to the aminoterminal end of diphtheria toxin are translocated to the cytosol. J. Cell Biol., 113, 1025-1032.
32. VAN DEN EYNDE B. J. and VAN DER BRUGGEN P. (1997): T cell defined tumor antigens. Curr. Opin. Immunol., 9, 684-693.
33. AN PEL A., VAN DER BRUGGEN P., COULIE P. G., BRICHARD V. G., LETHE B., VAN DEN EYNDE B., UYTTENHOVE C., RENAULD J. C. and BOON T. (1995): Genes coding for tumor antigenes recognized by cytolytic T lymphocytes. Immunol. Rev., 145, 229-250.
34. WIȨDŁOCHA A. (1997): Diphtheria toxin as a molecular tool in the study of acidic fibroblast growth factor. Review. Arch. Immunol. Ther. Exp., 45, 391-409.
35. WIȨDŁOCHA A., FALNES P. Ø., MADSHUS I. H., SANDVIG K. and OLSNES S. (1994): Dual mode of signal transduction by externally added acidic fibroblast growth factor. Cell, 76, 1039-1051.
36. WIȨDŁOCHA A., FALNES P. ø., RAPAK A., MUNOZ R., KLINGENBERG O. and OLSNES S. (1996): Stimulation of proliferation of a human osteosarcoma cell line by exogenous acidic fibroblast growth factor required both activation of receptor kinase and growth factor internalization. Mol. Cell. Biol., 16, 270-280.
37. WIȨDŁOCHA A., MADSHUS I. H., MACH H., MIDDAUGH C. R. and OLSNES S. (1992): Tight folding of acidic fibroblast growth factor prevents its translocation to the cytosol with diphtheria toxin as vector. EMBO J., 11, 4835-4842.
38. WIERTZ E. J. H. J., TORTORELLA D., BOGYO M., YU J., MOTHES W., JONES T. R., RAPOPORT T. A. and PLOEGH H. L. (1996): Sec-61 mediated transport of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature, 384, 432-438.
39. WILIAMS D. B., VASSILAKOS A. and SUH W. K. (1996): Peptide presentation by MHC class I molecules. Trends Cell Biol., 6, 267-273.
40. WONG K. K. and CHATTERJEE S. (1996): Adeno-associated virus based vectors as antivirals. In: Adeno-associated virus (AAV) vectors in gene therapy. Curr. Top. Microbiol. Immunol., 218, 145-171.
41. XU L., SANCHES A., YANG Z-Y., ZAKI S. R., NABEL E. G., NICHOL S. T. and NABEL G. J. (1998): Immunization for Ebola virus infection. Nature, 4, 37-42.
42. YAKOW I. M., DERBY M. A., AHLERS J. J., KELSALL B., EARL P., Moss B., STROBER W. and BERZOFSKY J. A. (1998): Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. USA, 95, 1709-1714.